sugammadex medichem 100 mg/ml solution for injection (2 ml vial)
medichem, s.a. fructuós gelabert 6-8, 08970, sant joan despí, (barcellona), spain - sugammadex - solution for injection - sugammadex 200 mg - all other therapeutic products
sugammadex medichem 100 mg/ml solution for injection (5 ml vial)
medichem, s.a. fructuós gelabert 6-8, 08970, sant joan despí, (barcellona), spain - sugammadex - solution for injection - sugammadex 500 mg - all other therapeutic products
sugammadex pharmazac solution for injection 100mg/ml (2ml vial)
pharmazac, s.a. 31 naousis str., 104 47, athens,, greece - sugammadex - solution for injection - sugammadex 200 mg - all other therapeutic products
sugammadex pharmazac solution for injection 100mg/ml (5ml vial)
pharmazac, s.a. 31 naousis str., 104 47, athens,, greece - sugammadex - solution for injection - sugammadex 500 mg - all other therapeutic products
sugammadex- sugammadex injection
patheon manufacturing services llc - sugammadex (unii: 361lpm2t56) (sugammadex sodium - unii:erj6x2mxv7) - sugammadex 500 mg in 5 ml
sugammadex- sugammadex injection sugammadex- sugammadex injection, solution
camber pharmaceuticals, inc. - sugammadex sodium (unii: erj6x2mxv7) (sugammadex - unii:361lpm2t56) - sugammadex injection is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery. pediatric use information is approved for merck sharp & dohme corp., a subsidiary of merck & co. inc.’s bridion ® (sugammadex injection). however, due to merck sharp & dohme corp., a subsidiary of merck & co. inc.’s marketing exclusivity rights, this drug product is not labeled with that information. sugammadex is contraindicated in patients with known hypersensitivity to sugammadex or any of its components. hypersensitivity reactions that occurred varied from isolated skin reactions to serious systemic reactions (i.e., anaphylaxis, anaphylactic shock) and have occurred in patients with no prior exposure to sugammadex [see warnings and precautions (5.1), adverse reactions (6)]. risk summary there are no clinical trial data on sugammadex use in pregnant women to inform any drug-associated risks. the available data from
sugammadex piramal
piramal critical care b.v. - sugammadex sodium - neuromuscular blockade - sugammadex - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.
sugammadex mylan
mylan ireland limited - sugammadex sodium - neuromuscular blockade - all other therapeutic products - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
sugammadex fresenius kabi
fresenius kabi deutschland gmbh - sugammadex sodium - neuromuscular blockade - all other therapeutic products - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
sugammadex amomed
aop orphan pharmaceuticals gmbh - sugammadex sodium - neuromuscular blockade - all other therapeutic products - reversal of neuromuscular blockade induced by rocuronium or vecuronium.for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.